LifeVantage Corporation — Form 10-Q Summary
Business context and reporting period. The filing covers the quarter and six months ended December 31, 2011. LifeVantage sells Protandim dietary supplements and TrueScience skin-care products, primarily through independent distributors in the Americas and Japan. The company reports one operating segment.
Financial results and liquidity
| Metric | Quarter ended Dec. 31, 2011 | Quarter ended Dec. 31, 2010 | Six months ended Dec. 31, 2011 | Six months ended Dec. 31, 2010 |
|---|---|---|---|---|
| Net sales | $25.3 million | $7.5 million | $45.4 million | $13.9 million |
| Gross profit / margin | $21.6 million / 85% | $6.3 million / 84% | $38.7 million / 85% | $11.7 million / 84% |
| Operating income | $4.3 million | $0.6 million | $7.7 million | $1.0 million |
| Net income | $8.8 million | $5.4 million | $12.5 million | $6.2 million |
| Operating cash flow | Not separately reported by quarter | $8.0 million | $1.1 million |
- For the six months, operating expenses were $31.0 million, up from $10.7 million. Sales and marketing expense rose to $24.4 million, primarily reflecting distributor commissions on higher sales.
- Cash and cash equivalents were $13.5 million at December 31, versus $6.4 million at June 30, 2011. Working capital was $5.6 million, compared with a deficit of $3.1 million.
- The company had $433,948 outstanding on its revolving line of credit at December 31; it reported the line was paid in full in January 2012. No long-term borrowing balance was reported at quarter-end. Current liabilities included $6.1 million of derivative liabilities.
- Stockholders’ equity was $9.3 million, compared with a deficit of $20.8 million at June 30. The change includes a $16.5 million reclassification of warrant liabilities to equity following a warrant amendment.
Material changes and unusual items
- Sales increased by $17.8 million for the quarter and $31.5 million for the six-month period, driven by higher network-channel volume in the Americas and Japan. Six-month sales were $33.9 million in the Americas and $11.5 million in Japan.
- Net income includes noncash gains from changes in derivative fair value: $3.1 million for the quarter and $3.9 million for six months. These gains were lower than the comparable prior-year gains and materially affect the comparison of reported profit.
- The company recorded a $2.8 million tax benefit from releasing its deferred-tax valuation allowance, based on management’s conclusion that realization of the deferred tax asset was more likely than not. The six-month income tax benefit was $837,459.
- Basic and diluted earnings per share for the quarter were $0.09 and $0.05, respectively; for the six months, $0.13 and $0.07. Weighted-average diluted shares were approximately 121.2 million for the quarter and 121.0 million for six months.
Outlook, risks and contingencies
- Management said it expects gross margins for the network marketing channel to remain around the reported range and expects operating expenses to rise with sales and continued growth. It stated that research and development funding of up to approximately 2% of net sales was available for the remainder of the fiscal year; spending timing depends on specific projects.
- Management believes cash on hand and expected future operating cash flow will fund operations for at least 12 months. Lower-than-projected sales could require expense cuts or additional financing, which may be unavailable or dilutive.
- Disclosure controls were deemed ineffective at December 31, 2011 because of material weaknesses involving accounting staffing and technical expertise, and insufficient oversight and documentation. Management had begun remediation and expected to test updated controls by June 30, 2012. The filing notes material audit adjustments to the 2011 financial statements.
- A distributor-related lawsuit filed in Utah seeks more than $5 million in compensatory damages and more than $3 million in punitive damages, plus fees and costs. The company disputes the allegations and intends to defend the case; discovery had begun.
- Key risks include reliance on a primary product and distributor channel, distributor retention and conduct, regulation of supplements and network marketing, third-party manufacturing and raw-material availability, product returns, international operations, and potential financing and dilution. The company also reports concentration of cash balances above federally insured limits.
Investor verification priorities
- Separate operating performance from the derivative fair-value gains and one-time deferred-tax valuation-allowance release when assessing earnings quality.
- Review remediation progress and subsequent testing of the disclosed material weaknesses in financial reporting controls.
- Monitor distributor growth, sales concentration by geography and product, return reserves, and whether sales momentum can be sustained.
- Track the Utah litigation and any changes to the company’s assessment or potential exposure.
- Confirm the January 2012 line-of-credit repayment and assess future liquidity, spending needs, and potential dilution from options, warrants, or new financing.